Replimune's $97.9 Million Hercules Loan Now Carries A $1.2 Billion Market-Cap Test

The cancer-drug developer's debt covenant offers three ways to pass as its first product, TUDRIQEV, reaches patients.

Share
Replimune's $97.9 Million Hercules Loan Now Carries A $1.2 Billion Market-Cap Test

Replimune, which develops cancer treatments built on an engineered herpes virus, owes Hercules Capital a $97,882 thousand principal balance, and a covenant on that loan now forces it to clear one of three bars: product sales, a market value above $1.2 billion, or a large cash cushion. The disclosure comes in its 10-Q, filed Wednesday, as its first approved drug, TUDRIQEV, begins shipping.

Three ways to pass the covenant

Starting on the later of July 1, 2026 or the date principal reaches $100.0 million, Replimune must meet one test: a minimum amount of trailing three-month net product revenue, tested monthly; a market capitalization above $1.2 billion with unrestricted cash of at least 50% of the loan; or unrestricted cash of at least 85% of the loan.

A separate, older covenant requires unrestricted cash of at least 35% of secured obligations at all times.

The principal stood at $82,252 thousand on March 31, 2026. It rose after a $15.0 million draw on September 29, when the company closed a Fourth Amendment with Hercules. The amendment also allows one more advance of up to $15.0 million on or before March 31, 2027, within a facility that still tops out at $200.0 million. The prior quarter's 10-Q did not describe that amendment.

A launch with first sales still ahead

Replimune said the FDA granted TUDRIQEV accelerated approval on August 6. The drug became commercially available October 1, and providers began ordering October 2. The company says about 20 melanoma institutions have put it on formulary and, as of October 23, more than 15 have written prescriptions. It reports no product revenue yet.

The approval extended the loan's maturity to October 1, 2029. Replimune raised approximately $141.0 million net in an August equity offering, which the filing says alleviated the going-concern doubt cited in its annual report. Cash and equivalents were $307.8 million at September 30, which management says funds operations for more than twelve months.

Inventory of $9,867 thousand now sits on the balance sheet, against none at March 31, because costs are capitalized after approval.

Losses narrow as spending shifts

Net loss was $57.1 million for the quarter ended September 30, against $83.1 million a year earlier. Research spending fell to $34.4 million from $57.9 million, helped by an April restructuring.

Replimune's next quarterly report should show whether product revenue is large enough to use the first covenant test.

Replimune's next quarterly report should show its first product revenue.

Sources

More on Replimune Group

All Replimune Group (REPL) coverage →